TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQX: ATBPF) today announced that it has retained MKR Group, Inc. (“MKR”) to create and execute a new proactive investor relations program addressing institutional investors and sell-side contacts in the U.S. financial markets. MKR will support the company’s North American shareholder development efforts.
“As we begin to reach significant milestones in our business, the U.S. financial markets will become increasingly important to realize the full potential for our company,” said Dan Legault, Antibe’s CEO. “Teaming with MKR will help us expand our institutional ownership and exposure in the U.S. MKR is well known for its expertise with small cap growth stocks and cross-border operations, so we are excited to begin this next phase of shareholder development with them as our partner.”
MKR will handle all elements of U.S. investor outreach with an emphasis on institutional managers and sell-side analysts. The agreement with MKR, which is subject to the approval of the TSX Venture Exchange, has an initial term of 3 months and can be terminated by either party on 30 days prior notice thereafter. MKR will receive a fee of US$4,000 per month. MKR is a respected investor relations firm based in Los Angeles, California, is independent of Antibe and does not have any interest, directly or indirectly, in securities of Antibe or any right to acquire such interest.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its ability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.